Durata Therapeutics Inc  

(Public, NASDAQ:DRTX)   Watch this stock  
Find more results for DRTX
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.76
Shares 26.79M
Beta     -
Inst. own 92%
Nov 11, 2014
Durata Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Q3 2014 Durata Therapeutics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -199.30% -
Operating margin -181.17% -
EBITD margin - -
Return on average assets -99.75% -66.57%
Return on average equity - -150.73%
Employees 68 -
CDP Score - -


200 S Wacker Dr Ste 2550
CHICAGO, IL 60606-5811
United States - Map
+1-312-2197000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.